RESUMEN
BACKGROUND: Mutations in the Plasmodium falciparum dhfr gene confer resistance to pyrimethamine, which is widely used for malaria chemoprevention in Africa. We aimed to evaluate the frequency and evolution of dhfr mutations in Plasmodium ovale spp in Africa and their functional consequences, which are incompletely characterised. METHODS: We analysed dhfr mutations and their frequencies in P ovale spp isolates collected between Feb 1, 2004, and Aug 31, 2023, from the French National Malaria Reference Centre collection and from field studies in Benin, Gabon, and Kenya. Genetic patterns of positive selection were investigated. Full-length recombinant wild-type and mutant DHFR enzymes from both P ovale curtisi and P ovale wallikeri were expressed in bacteria to test whether the most common mutations reduced pyrimethamine susceptibility. FINDINGS: We included 518 P ovale spp samples (314 P ovale curtisi and 204 P ovale wallikeri). In P ovale curtisi, Ala15Ser-Ser58Arg was the most common dhfr mutation (39%; 124 of 314 samples). In P ovale wallikeri, dhfr mutations were less frequent, with Phe57Leu-Ser58Arg reaching 17% (34 of 204 samples). These two mutants were the most prevalent in central and east Africa and were fixed in Kenyan isolates. We detected six and four other non-synonymous mutations, representing 8% (24 isolates) and 2% (five isolates) of the P ovale curtisi and P ovale wallikeri isolates, respectively. Whole-genome sequencing and microsatellite analyses revealed reduced genetic diversity around the mutant pocdhfr and powdhfr genes. The mutant DHFR proteins showed structural changes at the pyrimethamine binding site in-silico, confirmed by a 4-times increase in pyrimethamine half-maximal inhibitory concentration in an Escherichia coli growth assay for the Phe57Leu-Ser58Arg mutant and 50-times increase for the Ala15Ser-Ser58Arg mutant, compared with the wild-type counterparts. INTERPRETATION: The widespread use of sulfadoxine-pyrimethamine for malaria chemoprevention might have exerted fortuitous selection pressure for dhfr mutations in P ovale spp. This calls for closer monitoring of dhfr and dhps mutations in P ovale spp. FUNDING: French Ministry of Health, Agence Nationale de la Recherche, and Global Emerging Infections Surveillance branch of the Armed Forces Health Surveillance Division.
Asunto(s)
Antimaláricos , Resistencia a Medicamentos , Malaria , Mutación , Plasmodium ovale , Pirimetamina , Tetrahidrofolato Deshidrogenasa , Tetrahidrofolato Deshidrogenasa/genética , Tetrahidrofolato Deshidrogenasa/metabolismo , Pirimetamina/farmacología , Pirimetamina/uso terapéutico , Resistencia a Medicamentos/genética , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Plasmodium ovale/genética , Plasmodium ovale/efectos de los fármacos , Humanos , Malaria/epidemiología , Estudios Retrospectivos , África del Sur del Sahara/epidemiología , Proteínas Protozoarias/genética , Kenia/epidemiologíaRESUMEN
New prophylactic drugs against malaria infections are urgently needed. We conducted randomized, double-blind, placebo-controlled, phase 2 trials of a new antimalarial drug combination, naphthoquine-azithromycin (NQAZ), to determine its safety and protective efficacy in a low-endemicity area of Southeast Asia. In the first trial, 127 healthy volunteers were randomized to receive two single doses of either 400 mg of NQAZ (200 mg of each drug), 800 mg of NQAZ (400 mg of each drug), or placebo on day 0 and day 30. Weekly follow-ups were performed for 2 months, and physical and clinical laboratory exams were done during the second and eighth week. Both drug regimens were well tolerated, without any serious adverse events. Four adverse events (transient and slight elevations of serum transaminase concentrations) were found only in the two drug-treated groups and thus might be drug-related. In the second trial, 353 volunteer villagers were randomized into the same three groups as in the first trial, and malaria infections were followed for a month. For the intention-to-treat analysis, both regimens offered greater than 90% prophylactic efficacies against all malaria infections. When the analysis was done according to parasite species, 400 mg and 800 mg NQAZ provided 81.63 and 90.59% prophylactic efficacies, respectively, against Plasmodium falciparum infections, whereas both offered 100% prophylactic efficacy against Plasmodium vivax and Plasmodium ovale These trials showed that NQAZ had a good safety profile, and monthly single doses of 400 mg or 800 mg for adults offered excellent prophylaxis against malaria infections, especially the two relapsing species.
Asunto(s)
1-Naftilamina/análogos & derivados , Aminoquinolinas/uso terapéutico , Antimaláricos/uso terapéutico , Azitromicina/uso terapéutico , Malaria Falciparum/prevención & control , Malaria Vivax/prevención & control , 1-Naftilamina/efectos adversos , 1-Naftilamina/uso terapéutico , Adolescente , Adulto , Aminoquinolinas/efectos adversos , Antimaláricos/efectos adversos , Azitromicina/efectos adversos , Quimioprevención/métodos , Niño , China , Método Doble Ciego , Quimioterapia Combinada , Femenino , Voluntarios Sanos , Humanos , Malaria Falciparum/tratamiento farmacológico , Malaria Vivax/tratamiento farmacológico , Masculino , Persona de Mediana Edad , Plasmodium falciparum/efectos de los fármacos , Plasmodium ovale/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Adulto JovenRESUMEN
Important strides have been made within the past decade toward malaria elimination in many regions, and with this progress, the feasibility of eradication is once again under discussion. If the ambitious goal of eradication is to be achieved by 2040, all species of Plasmodium infecting humans will need to be targeted with evidence-based and concerted interventions. In this perspective, the potential barriers to achieving global malaria elimination are discussed with respect to the related diversities in host, parasite, and vector populations. We argue that control strategies need to be reorientated from a sequential attack on each species, dominated by Plasmodium falciparum to one that targets all species in parallel. A set of research themes is proposed to mitigate the potential setbacks on the pathway to a malaria-free world.
Asunto(s)
Erradicación de la Enfermedad/métodos , Malaria Falciparum/prevención & control , Malaria Vivax/prevención & control , Malaria/prevención & control , Animales , Anopheles/parasitología , Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Erradicación de la Enfermedad/economía , Interacciones Huésped-Parásitos , Humanos , Malaria/tratamiento farmacológico , Malaria/inmunología , Malaria/parasitología , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/inmunología , Malaria Falciparum/parasitología , Malaria Vivax/tratamiento farmacológico , Malaria Vivax/inmunología , Malaria Vivax/parasitología , Mosquitos Vectores/parasitología , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/inmunología , Plasmodium falciparum/patogenicidad , Plasmodium knowlesi/efectos de los fármacos , Plasmodium knowlesi/inmunología , Plasmodium knowlesi/patogenicidad , Plasmodium malariae/efectos de los fármacos , Plasmodium malariae/inmunología , Plasmodium malariae/patogenicidad , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/inmunología , Plasmodium ovale/patogenicidad , Plasmodium vivax/efectos de los fármacos , Plasmodium vivax/inmunología , Plasmodium vivax/patogenicidad , Primaquina/uso terapéuticoRESUMEN
Treatment recommendations for Plasmodium malariae and Plasmodium ovale malaria are largely based on anecdotal evidence. The aim of this prospective study, conducted in Gabon, was to systematically assess the efficacy and safety of artemether-lumefantrine for the treatment of patients with uncomplicated P. malariae or P. ovale species monoinfections or mixed Plasmodium infections. Patients with microscopically confirmed P. malariae, P. ovale, or mixed-species malaria with at least one of these two Plasmodium species were treated with an oral, fixed-dose combination of artemether-lumefantrine for 3 consecutive days. The primary endpoints were per-protocol PCR-corrected adequate clinical and parasitological response (ACPR) on days 28 and 42. Tolerability and safety were recorded throughout the follow-up period. Seventy-two participants (42 male and 30 female) were enrolled; 62.5% of them had PCR-corrected mixed Plasmodium infections. Per protocol, PCR-corrected ACPR rates were 96.6% (95% confidence interval [CI], 91.9 to 100) on day 28 and 94.2% (95% CI, 87.7 to 100) on day 42. Considering Plasmodium species independently from their coinfecting species, day 42 ACPR rates were 95.5% (95% CI, 89.0 to 100) for P. falciparum, 100% (exact CI, 84.6 to 100) for P. malariae, 100% (exact CI, 76.8 to 100) for P. ovale curtisi, and 90.9% (95% CI, 70.7 to 100) for P. ovale wallikeri Study drug-related adverse events were generally mild or moderate. In conclusion, this clinical trial demonstrated satisfying antimalarial activity of artemether-lumefantrine against P. ovalewallikeri, P. ovale curtisi, P. malariae, and mixed Plasmodium infections, with per-protocol efficacies of 90% to 100% and without evident tolerability or safety concerns. (This trial was registered in the clinical study database ClinicalTrials.gov under the identifier NCT02528279.).
Asunto(s)
Antimaláricos/uso terapéutico , Arteméter/uso terapéutico , Lumefantrina/uso terapéutico , Plasmodium malariae/patogenicidad , Plasmodium ovale/patogenicidad , Adolescente , Adulto , Niño , Preescolar , Femenino , Gabón , Humanos , Masculino , Plasmodium malariae/efectos de los fármacos , Plasmodium malariae/genética , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/genética , Adulto JovenRESUMEN
BACKGROUND: Despite increased efforts to control and ultimately eradicate human malaria, Plasmodium ovale malaria is for the most part outside the focus of research or public health programmes. Importantly, the understanding of P. ovale-nowadays regarded as the two distinct species P. ovale wallikeri and P. ovale curtisi-largely stems from case reports and case series lacking study designs providing high quality evidence. Consecutively, there is a lack of systematic evaluation of the clinical presentation, appropriate treatment and relapse characteristics of P. ovale malaria. The aim of this systematic review is to provide a systematic appraisal of the current evidence for severe manifestations, relapse characteristics and treatment options for human P. ovale malaria. METHODS AND RESULTS: This systematic review was performed according to the PRISMA guidelines and registered in the international prospective register for systematic reviews (PROSPERO 2016:CRD42016039214). P. ovale mono-infection was a strict inclusion criterion. Of 3454 articles identified by the literature search, 33 articles published between 1922 and 2015 met the inclusion criteria. These articles did not include randomized controlled trials. Five prospective uncontrolled clinical trials were performed on a total of 58 participants. P. ovale was sensitive to all tested drugs within the follow-up periods and on interpretable in vitro assays. Since its first description in 1922, only 18 relapsing cases of P. ovale with a total of 28 relapse events were identified in the scientific literature. There was however no molecular evidence for a causal relationship between dormant liver stages and subsequent relapses. A total of 22 severe cases of P. ovale malaria were published out of which five were fatal. Additionally, two cases of congenital P. ovale malaria were reported. CONCLUSIONS: Current knowledge of P. ovale malaria is based on small trials with minor impact, case reports and clinical observations. This systematic review highlights that P. ovale is capable of causing severe disease, severe congenital malaria and may even lead to death. Evidence for relapses in patients with P. ovale malaria adds up to only a handful of cases. Nearly 100 years after P. ovale's first description by Stephens the evidence for the clinical characteristics, relapse potential and optimal treatments for P. ovale malaria is still scarce.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria/tratamiento farmacológico , Malaria/patología , Plasmodium ovale/aislamiento & purificación , Antimaláricos/farmacología , Humanos , Malaria/parasitología , Plasmodium ovale/efectos de los fármacos , RecurrenciaRESUMEN
Malaria recurrences after an initially successful therapy and malarial fever occurring a long time after infection are well-known problems in malariology. Currently, two distinct types of malaria recurrences are defined: recrudescence and relapse. A recrudescence is thought to originate from circulating Plasmodium blood stages which do not cause fever before a certain level of a microscopically detectable parasitemia is reached. Contrary, a relapse is thought to originate from quiescent intracellular hepatic parasite stages called hypnozoites. Recrudescences would typically occur in infections due to Plasmodium falciparum. Plasmodium knowlesi, and Plasmodium malariae, whereas relapses would be caused exclusively by Plasmodium vivax and Plasmodium ovale. This schematic view is, however, insufficiently supported by experimental evidence. For instance, hypnozoites of P. ovale have never been experimentally documented. On the other hand, the nonfinding of P. malariae hypnozoites turned into the proof for the nonexistence of P. malariae hypnozoites. Clinical relapse-type recurrences have been observed in both P. ovale and P. malariae infections, and decade-long incubation times have also been reported in P. falciparum infections. We propose a gradual hypothesis in accordance with the continuity concept of biological evolution: both, relapse and recrudescence may be potentially caused by all Plasmodium spp. We hypothesize that the difference between the various Plasmodium spp. is quantitative rather than qualitative: there are Plasmodium spp. which frequently cause relapses such as P. vivax, particularly the P.v. Chesson strain, species which cause relapses less frequently, such as P. ovale and sometimes P. malariae, and species which may exceptionally cause relapses such as P. falciparum. All species may cause recrudescences. As clinical consequences, we propose that 8-aminquinolines may be considered in a relapse-type recrudescence regardless of the causal Plasmodium sp., whereas primaquine relapse prevention might not be routinely indicated in malaria due to P. ovale.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria/veterinaria , Plasmodium/fisiología , Aminoquinolinas/uso terapéutico , Humanos , Hígado/parasitología , Malaria/tratamiento farmacológico , Malaria/parasitología , Parasitemia , Plasmodium/efectos de los fármacos , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/fisiología , Plasmodium knowlesi/efectos de los fármacos , Plasmodium knowlesi/fisiología , Plasmodium malariae/efectos de los fármacos , Plasmodium malariae/fisiología , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/fisiología , Plasmodium vivax/efectos de los fármacos , Plasmodium vivax/fisiología , Primaquina/uso terapéutico , Recurrencia , Especificidad de la EspecieRESUMEN
Artemisinin resistance in Plasmodium falciparum, the agent of severe malaria, is currently a major obstacle to malaria control in Southeast Asia. A gene named "kelch13" has been associated with artemisinin resistance in P. falciparum The orthologue of the kelch gene in P. vivax was identified and a small number of mutations were found in previous studies. The kelch orthologues in the other two human malaria parasites, P. malariae and P. ovale, have not yet been studied. Therefore, in this study, the orthologous kelch genes of P. malariae, P. ovale wallikeri, and P. ovale curtisi were isolated and analyzed for the first time. The homologies of the kelch genes of P. malariae and P. ovale were 84.8% and 82.7%, respectively, compared to the gene in P. falciparum kelch polymorphisms were studied in 13 P. malariae and 5 P. ovale isolates from Thailand. There were 2 nonsynonymous mutations found in these samples. One mutation was P533L, which was found in 1 of 13 P. malariae isolates, and the other was K137R, found in 1 isolate of P. ovale wallikeri (n = 4). This result needs to be considered in the context of widespread artemisinin used within the region; their functional consequences for artemisinin sensitivity in P. malariae and P. ovale will need to be elucidated.
Asunto(s)
Plasmodium malariae/genética , Plasmodium ovale/genética , Polimorfismo Genético/genética , Antimaláricos/uso terapéutico , Artemisininas/uso terapéutico , Humanos , Malaria Falciparum/tratamiento farmacológico , Malaria Falciparum/parasitología , Mutación , Plasmodium malariae/efectos de los fármacos , Plasmodium malariae/aislamiento & purificación , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/aislamiento & purificación , TailandiaRESUMEN
BACKGROUND: Pregnancy has been reported to alter the pharmacokinetic properties of anti-malarial drugs, including the different components of artemisinin-based combination therapy (ACT). However, small sample sizes make it difficult to draw strong conclusions based on individual pharmacokinetic studies. The aim of this review is to summarize the evidence of the influence of pregnancy on the pharmacokinetic properties of different artemisinin-based combinations. METHODS: A PROSPERO-registered systematic review to identify clinical trials that investigated the influence of pregnancy on the pharmacokinetic properties of different forms of ACT was conducted, following PRISMA guidelines. Without language restrictions, Medline/PubMed, Embase, Cochrane Central Register of Controlled Trials, Web of Science, LILACS, Biosis Previews and the African Index Medicus were searched for studies published up to November 2015. The following components of ACT that are currently recommend by the World Health Organization as first-line treatment of malaria in pregnancy were reviewed: artemisinin, artesunate, dihydroartemisinin, lumefantrine, amodiaquine, mefloquine, sulfadoxine, pyrimethamine, piperaquine, atovaquone and proguanil. RESULTS: The literature search identified 121 reports, 27 original studies were included. 829 pregnant women were included in the analysis. Comparison of the available studies showed lower maximum concentrations (Cmax) and exposure (AUC) of dihydroartemisinin, the active metabolite of all artemisinin derivatives, after oral administration of artemether, artesunate and dihydroartemisinin in pregnant women. Low day 7 concentrations were commonly seen in lumefantrine studies, indicating a low exposure and possibly reduced efficacy. The influence of pregnancy on amodiaquine and piperaquine seemed not to be clinically relevant. Sulfadoxine plasma concentration was significantly reduced and clearance rates were higher in pregnancy, while pyrimethamine and mefloquine need more research as no general conclusion can be drawn based on the available evidence. For atovaquone, the available data showed a lower maximum concentration and exposure. Finally, the maximum concentration of cycloguanil, the active metabolite of proguanil, was significantly lower, possibly compromising the efficacy. CONCLUSION: These findings suggest that reassessment of the dose of the artemisinin derivate and some components of ACT are necessary to ensure the highest possible efficacy of malaria treatment in pregnant women. However, for most components of ACT, data were insufficient and extensive research with larger sample sizes will be necessary to identify the exact influences of pregnancy on the pharmacokinetic properties of different artemisinin-based combinations. In addition, different clinical studies used diverse study designs with various reported relevant outcomes. Future pharmacokinetic studies could benefit from more uniform designs, in order to increase quality, robustness and effectiveness. STUDY REGISTRATION: CRD42015023756 (PROSPERO).
Asunto(s)
Artemisininas/farmacocinética , Antimaláricos/farmacocinética , Antimaláricos/farmacología , Antimaláricos/uso terapéutico , Artemisininas/farmacología , Artemisininas/uso terapéutico , Combinación de Medicamentos , Femenino , Humanos , Malaria/tratamiento farmacológico , Malaria/fisiopatología , Plasmodium falciparum/efectos de los fármacos , Plasmodium ovale/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , EmbarazoRESUMEN
We report the first case of an imported Plasmodium ovale relapse in a Tunisian man who developed malaria three years after leaving sub- Saharan Africa. A 29-year-old Tunisian man consulted in September 2011 because of a fever, myalgia, and headache that had begun eight days earlier and persisted despite treatment with oral antibiotics. On questioning, the patient stated that he had resided three years ago for six months in Ivory Coast, where he acquired malaria. He was treated with artemether-lumefantrine. The patient said he had no recent travel to any other malaria-endemic area and had not received a blood transfusion. A first microscopy of peripheral blood smears was negative for malaria parasites. The diagnosis was established 17 days after onset of symptoms. A repeat microscopic examination of blood smears confirmed the presence of Plasmodium ovale with a parasitemia lower than 0.1%. The patient was treated with artemether lumefantrine, followed by primaquine. This case emphasizes the possibility of relapse of some plasmodial species. It highlights the importance of repeating microscopic examination of blood when the diagnosis of malaria is suspected.
Asunto(s)
Malaria/diagnóstico , Malaria/parasitología , Plasmodium ovale/aislamiento & purificación , Adulto , Antimaláricos/uso terapéutico , Combinación Arteméter y Lumefantrina , Artemisininas/uso terapéutico , Côte d'Ivoire , Combinación de Medicamentos , Etanolaminas/uso terapéutico , Fluorenos/uso terapéutico , Humanos , Malaria/tratamiento farmacológico , Masculino , Plasmodium ovale/efectos de los fármacos , Primaquina/uso terapéutico , Recurrencia , Viaje , Resultado del Tratamiento , TúnezRESUMEN
BACKGROUND: The undetectable hypnozoite reservoir for relapsing Plasmodium vivax and P. ovale malarias presents a major challenge for malaria control and elimination in endemic countries. This study aims to directly determine the contribution of relapses to the burden of P. vivax and P. ovale infection, illness, and transmission in Papua New Guinean children. METHODS AND FINDINGS: From 17 August 2009 to 20 May 2010, 524 children aged 5-10 y from East Sepik Province in Papua New Guinea (PNG) participated in a randomised double-blind placebo-controlled trial of blood- plus liver-stage drugs (chloroquine [CQ], 3 d; artemether-lumefantrine [AL], 3 d; and primaquine [PQ], 20 d, 10 mg/kg total dose) (261 children) or blood-stage drugs only (CQ, 3 d; AL, 3 d; and placebo [PL], 20 d) (263 children). Participants, study staff, and investigators were blinded to the treatment allocation. Twenty children were excluded during the treatment phase (PQ arm: 14, PL arm: 6), and 504 were followed actively for 9 mo. During the follow-up time, 18 children (PQ arm: 7, PL arm: 11) were lost to follow-up. Main primary and secondary outcome measures were time to first P. vivax infection (by qPCR), time to first clinical episode, force of infection, gametocyte positivity, and time to first P. ovale infection (by PCR). A basic stochastic transmission model was developed to estimate the potential effect of mass drug administration (MDA) for the prevention of recurrent P. vivax infections. Targeting hypnozoites through PQ treatment reduced the risk of having at least one qPCR-detectable P. vivax or P. ovale infection during 8 mo of follow-up (P. vivax: PQ arm 0.63/y versus PL arm 2.62/y, HR = 0.18 [95% CI 0.14, 0.25], p < 0.001; P. ovale: 0.06 versus 0.14, HR = 0.31 [95% CI 0.13, 0.77], p = 0.011) and the risk of having at least one clinical P. vivax episode (HR = 0.25 [95% CI 0.11, 0.61], p = 0.002). PQ also reduced the molecular force of P. vivax blood-stage infection in the first 3 mo of follow-up (PQ arm 1.90/y versus PL arm 7.75/y, incidence rate ratio [IRR] = 0.21 [95% CI 0.15, 0.28], p < 0.001). Children who received PQ were less likely to carry P. vivax gametocytes (IRR = 0.27 [95% CI 0.19, 0.38], p < 0.001). PQ had a comparable effect irrespective of the presence of P. vivax blood-stage infection at the time of treatment (p = 0.14). Modelling revealed that mass screening and treatment with highly sensitive quantitative real-time PCR, or MDA with blood-stage treatment alone, would have only a transient effect on P. vivax transmission levels, while MDA that includes liver-stage treatment is predicted to be a highly effective strategy for P. vivax elimination. The inclusion of a directly observed 20-d treatment regime maximises the efficiency of hypnozoite clearance but limits the generalisability of results to real-world MDA programmes. CONCLUSIONS: These results suggest that relapses cause approximately four of every five P. vivax infections and at least three of every five P. ovale infections in PNG children and are important in sustaining transmission. MDA campaigns combining blood- and liver-stage treatment are predicted to be a highly efficacious intervention for reducing P. vivax and P. ovale transmission. TRIAL REGISTRATION: ClinicalTrials.gov NCT02143934.
Asunto(s)
Antimaláricos/uso terapéutico , Malaria/tratamiento farmacológico , Malaria/transmisión , Modelos Estadísticos , Plasmodium ovale/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Esporozoítos/efectos de los fármacos , Enfermedad Hepática Inducida por Sustancias y Drogas/prevención & control , Niño , Preescolar , Erradicación de la Enfermedad/tendencias , Método Doble Ciego , Femenino , Humanos , Masculino , Papúa Nueva Guinea/epidemiología , Placebos , Reacción en Cadena en Tiempo Real de la Polimerasa , Recurrencia , Resultado del TratamientoAsunto(s)
Antimaláricos/administración & dosificación , Malaria Vivax/tratamiento farmacológico , Malaria/tratamiento farmacológico , Plasmodium ovale/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Primaquina/administración & dosificación , Viaje , Femenino , Humanos , MasculinoRESUMEN
BACKGROUND: Recently, a dose of 30 mg (base) primaquine daily for 14 days is increasingly recommended for radical cure of Plasmodium vivax malaria. However, total primaquine doses, or those per body weight, are also recognized as important. In Japan, primaquine is not a licensed medicine, but has been used through the Research Group on Chemotherapy of Tropical Diseases for >3 decades. METHODS: Based on clinical records submitted to the Research Group, patients with P. vivax and Plasmodium ovale malaria treated with primaquine were analyzed to determine the efficacy and safety of the antimalarial drug. RESULTS: Seventy-five P. vivax cases, including 3 in children, and 19 P. ovale cases were enrolled. Five of the P. vivax cases demonstrated at least one relapse despite primaquine therapy. Total primaquine doses per body weight were obtained in 4 of the 5 relapsed patients, presenting 9 malaria episodes totally, and most of the primaquine failures were caused with a total dose ≤ 3.5 mg/kg. Liver function disturbance was reported in 2 cases. CONCLUSION: In order to optimize radical cure of P. vivax, the total primaquine dose per body weight should be considered, at least 3.5 mg/kg or even more if contracted in countries with significant drug resistance. Possibility of primaquine hepatotoxicity in chronic liver disease patients remains to be elucidated.
Asunto(s)
Antimaláricos/administración & dosificación , Malaria Vivax/tratamiento farmacológico , Malaria/tratamiento farmacológico , Plasmodium ovale/efectos de los fármacos , Plasmodium vivax/efectos de los fármacos , Primaquina/administración & dosificación , Viaje , Adulto , Pueblo Asiatico , Resistencia a Medicamentos , Femenino , Humanos , Japón , Hígado/efectos de los fármacos , Malaria Vivax/prevención & control , Masculino , Primaquina/efectos adversos , Recurrencia , Estudios Retrospectivos , Adulto JovenRESUMEN
BACKGROUND: A better understanding of the effect of malaria control interventions on vector and parasite populations, acquired immunity, and burden of the disease is needed to guide strategies to eliminate malaria from highly endemic areas. We monitored and analysed the changes in malaria epidemiology in a village community in Senegal, west Africa, over 22 years. METHODS: Between 1990 and 2012, we did a prospective longitudinal study of the inhabitants of Dielmo, Senegal, to identify all episodes of fever and investigate the relation between malaria host, vector, and parasite. Our study included daily medical surveillance with systematic parasite detection in individuals with fever. We measured parasite prevalence four times a year with cross-sectional surveys. We monitored malaria transmission monthly with night collection of mosquitoes. Malaria treatment changed over the years, from quinine (1990-94), to chloroquine (1995-2003), amodiaquine plus sulfadoxine-pyrimethamine (2003-06), and finally artesunate plus amodiaquine (2006-12). Insecticide-treated nets (ITNs) were introduced in 2008. FINDINGS: We monitored 776 villagers aged 0-101 years for 2â378â150 person-days of follow-up. Entomological inoculation rate ranged from 142·5 infected bites per person per year in 1990 to 482·6 in 2000, and 7·6 in 2012. Parasite prevalence in children declined from 87% in 1990 to 0·3 % in 2012. In adults, it declined from 58% to 0·3%. We recorded 23â546 fever episodes during the study, including 8243 clinical attacks caused by Plasmodium falciparum, 290 by Plasmodium malariae, and 219 by Plasmodium ovale. Three deaths were directly attributable to malaria, and two to severe adverse events of antimalarial drugs. The incidence of malaria attacks ranged from 1·50 attacks per person-year in 1990 to 2·63 in 2000, and to only 0·046 in 2012. The greatest changes were associated with the replacement of chloroquine and the introduction of ITNs. INTERPRETATION: Malaria control policies combining prompt treatment of clinical attacks and deployment of ITNs can nearly eliminate parasite carriage and greatly reduce the burden of malaria in populations exposed to intense perennial malaria transmission. The choice of drugs seems crucial. Rapid decline of clinical immunity allows rapid detection and treatment of novel infections and thus has a key role in sustaining effectiveness of combining artemisinin-based combination therapy and ITNs despite increasing pyrethroid resistance. FUNDING: Pasteur Institutes of Dakar and Paris, Institut de Recherche pour le Développement, and French Ministry of Cooperation.
Asunto(s)
Anopheles/parasitología , Insectos Vectores/parasitología , Malaria/epidemiología , Plasmodium falciparum/efectos de los fármacos , Plasmodium malariae/efectos de los fármacos , Plasmodium ovale/efectos de los fármacos , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Animales , Antimaláricos/administración & dosificación , Artemisininas/administración & dosificación , Niño , Preescolar , Estudios Transversales , Quimioterapia Combinada , Humanos , Lactante , Recién Nacido , Estudios Longitudinales , Malaria/tratamiento farmacológico , Malaria/prevención & control , Persona de Mediana Edad , Prevalencia , Estudios Prospectivos , Población Rural , Senegal/epidemiología , Adulto JovenRESUMEN
Only a few late cases of Plasmodium ovale presentation have been reported in literature. We describe two cases of late P. ovale presentation occurring in two French military personnel, 47 and 69 months, respectively, after a stay in Côte d'Ivoire and in the absence of new intercurrent malaria exposure.
Asunto(s)
Cloroquina/administración & dosificación , Malaria , Plasmodium ovale , Primaquina/administración & dosificación , Adulto , Antimaláricos/administración & dosificación , Côte d'Ivoire/epidemiología , Francia , Interacciones Huésped-Parásitos , Humanos , Malaria/sangre , Malaria/tratamiento farmacológico , Malaria/epidemiología , Malaria/etiología , Malaria/fisiopatología , Masculino , Personal Militar , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/aislamiento & purificación , Plasmodium ovale/fisiología , Factores de Tiempo , Viaje , Resultado del TratamientoRESUMEN
Since 2008, the French guidelines have promoted the systematic use of 30 mg/day of primaquine for the radical cure of Plasmodium vivax and Plamodium ovale infections. We observed three relapses in 10 patients with P vivax acquired in French Guiana. No relapses were seen in West African P ovale patients.
Asunto(s)
Malaria , Plasmodium ovale , Plasmodium vivax , Primaquina , Adulto , Antimaláricos/administración & dosificación , Antimaláricos/efectos adversos , Niño , Relación Dosis-Respuesta a Droga , Francia/epidemiología , Encuestas Epidemiológicas , Humanos , Malaria/diagnóstico , Malaria/tratamiento farmacológico , Malaria/epidemiología , Malaria/etiología , Masculino , Registros Médicos Orientados a Problemas , Cumplimiento de la Medicación , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/aislamiento & purificación , Plasmodium vivax/clasificación , Plasmodium vivax/efectos de los fármacos , Plasmodium vivax/aislamiento & purificación , Primaquina/administración & dosificación , Primaquina/efectos adversos , Prevención Secundaria , Resultado del TratamientoRESUMEN
We report a case of falciparum malaria in a traveler 9 days after successful treatment of ovale malaria. The underlying, cryptic mixed-species infection was primarily undetectable with standard laboratory diagnostics. This case highlights the limitations of these tests and the unpredictability of typical incubation periods in the individual case.
Asunto(s)
Artemisininas/administración & dosificación , Cloroquina/administración & dosificación , Coinfección , Etanolaminas/administración & dosificación , Fluorenos/administración & dosificación , Malaria , Plasmodium falciparum , Plasmodium ovale , Primaquina/administración & dosificación , Viaje , Antimaláricos/administración & dosificación , Combinación Arteméter y Lumefantrina , Cromatografía de Afinidad/métodos , Coinfección/sangre , Coinfección/tratamiento farmacológico , Coinfección/parasitología , Coinfección/fisiopatología , Combinación de Medicamentos , Sustitución de Medicamentos/métodos , Alemania , Humanos , Periodo de Incubación de Enfermedades Infecciosas , Malaria/sangre , Malaria/tratamiento farmacológico , Malaria/parasitología , Malaria/fisiopatología , Masculino , Microscopía/métodos , Persona de Mediana Edad , Nigeria , Parasitemia/diagnóstico , Plasmodium falciparum/efectos de los fármacos , Plasmodium falciparum/aislamiento & purificación , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/aislamiento & purificación , Resultado del TratamientoRESUMEN
Reports of potential drug-resistant strains of Plasmodium malariae in western Indonesia raise concerns that chloroquine resistance may be emerging in P. malariae and P. ovale. In order to assess this, in vivo and in vitro efficacy studies were conducted in patients with monoinfection in Papua, Indonesia. Consecutive patients with uncomplicated malaria due to P. ovale or P. malariae were enrolled in a prospective clinical trial, provided with supervised chloroquine treatment, and followed for 28 days. Blood from patients with P. malariae or P. ovale parasitemia greater than 1,000 per microliter underwent in vitro antimalarial drug susceptibility testing using a modified schizont maturation assay. Of the 57 evaluable patients in the clinical study (P. malariae, n = 46; P. ovale, n = 11), none had recurrence with the same species during follow-up. The mean parasite reduction ratio at 48 h was 86 (95% confidence interval [CI], 57 to 114) for P. malariae and 150 (95% CI, 54 to 245) for P. ovale (P = 0.18). One patient infected with P. malariae, with 93% of parasites at the trophozoite stage, was still parasitemic on day 4. In vitro drug susceptibility assays were carried out successfully for 40 isolates (34 infected with P. malariae and 6 with P. ovale). The P. malariae infections at trophozoite stages had significantly higher chloroquine 50% effective concentrations (EC(50)s) (median, 127.9 nM [range, 7.9 to 2,980]) than those initially exposed at the ring stage (median, 14.0 nM [range, 3.5 to 27.0]; P = 0.01). The EC(50) for chloroquine in P. ovale was also higher in an isolate initially at the trophozoite stage (23.2 nM) than in the three isolates predominantly at ring stage (7.8 nM). Chloroquine retains adequate efficacy against P. ovale and P. malariae, but its marked stage specificity of action may account for reports of delayed parasite clearance times.
Asunto(s)
Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Malaria/tratamiento farmacológico , Plasmodium malariae/efectos de los fármacos , Plasmodium ovale/efectos de los fármacos , Adolescente , Adulto , Niño , Preescolar , Femenino , Humanos , Indonesia , Malaria/microbiología , Masculino , Persona de Mediana Edad , Plasmodium malariae/patogenicidad , Plasmodium ovale/patogenicidad , Resultado del Tratamiento , Adulto JovenRESUMEN
A 27 week pregnant woman who had lived in Bangkok, Thailand, for 18 months presented to her obstetrician with a 1-week history of intermittent fever and malaise. Medical history was significant for multiple episodes of malaria during her 10 years of employment in sub-Saharan Africa before her relocation to Thailand. The initial malaria smear was negative. She returned a week later with no resolution of her symptoms, at which time she was found to have Plasmodium ovale by microscopy and polymerase chain reaction. She had an excellent response to chloroquine, which she continued weekly until 36 weeks of gestation. She delivered a healthy term infant and received radical cure with primaquine after cessation of breastfeeding. This case shows challenging issues in detection and management of imported P. ovale malaria.
Asunto(s)
Malaria/diagnóstico , Malaria/parasitología , Plasmodium ovale/aislamiento & purificación , Complicaciones Parasitarias del Embarazo/diagnóstico , Complicaciones Parasitarias del Embarazo/parasitología , Adulto , Animales , Antimaláricos/uso terapéutico , Cloroquina/uso terapéutico , Femenino , Humanos , Malaria/sangre , Malaria/tratamiento farmacológico , Plasmodium ovale/efectos de los fármacos , Plasmodium ovale/genética , Embarazo , Complicaciones Parasitarias del Embarazo/sangre , Complicaciones Parasitarias del Embarazo/tratamiento farmacológico , Primaquina/uso terapéutico , RecurrenciaRESUMEN
Liver function tests were performed in 61 vivax, 54 malariae and 15 ovale malaria patients who were admitted to Bangkok Hospital for Tropical Diseases between 2001 and 2004. The objective of the study was to evaluate changes in hepatic biochemical indices before and after treatment with artemisinin derivatives. On admission and prior to treatment, hepatic dysfunction was found among the 3 groups. Serum liver function tests and physical examinations were performed weekly during the 28-day follow-up period. Initially elevated serum bilirubin and diminished albumin returned to normal within 2 weeks of treatment. Serum alkaline phosphatase and aminotransferases returned to within normal limits within 3 weeks. We conclude that patients with Plasmodium vivax, P. malariae and P. ovale infections had slightly elevated serum bilirubin, aminotransferase and alkaline phosphatase levels, and hypoalbuminemia. These minor abnormalities returned to normal within a few weeks after treatment with therapies based on artemisinin derivatives.